Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

AYTU stock hub

Aytu BioPharma, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

AYTUis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

26.8M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

AYTU

In the news

Latest news · AYTU

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-109.2

P25 -105.6P50 -46.5P75 -3.1

ROIC-0.6

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All AYTU market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

212

Groups with data

Currency

USD

Showing 212 of 212 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001385818
Company name	Aytu BioPharma, Inc.
Country	United States
Country code	US
Cusip	054754874
Employees	83
Employees Change	-16%
Employees Change Percent	-16.16
Enterprise value	$18.9M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
Isin	US0547548588
Last refreshed	2026-05-10
Market cap	$26.8M
Market cap category	Nano-Cap
Price	$2.5
Price currency	USD
Rev Per Employee	754,698.8x
Sector	Healthcare
Sic	2834
Symbol	AYTU
Website	https://aytubio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-91.09%
EV Sales Forward	0.74x
EV/EBITDA	4.7x
EV/Sales	0.3x
FCF yield	-2.6%
P/B ratio	1.89x
P/S ratio	0.43x
PS Forward	1.05x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-0.66%
EBITDA Margin	6.43%
Gross margin	66.84%
Gross Profit	$41.9M
Gross Profit Growth	-5.24%
Gross Profit Growth Q	-10.77%
Gross Profit Growth3 Y	-11.72%
Gross Profit Growth5 Y	4.21%
Net Income	$-24.4M
Net Income Growth Years	3%
Pretax Margin	-38.7%
Profit Margin	-39.02%
Profit Per Employee	$-294,494
ROA	-0.22
Roa5y	-4.8
ROCE	-0.73
ROE	-109.2
Roe5y	-57.18
ROIC	-0.61

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-69.12%
Cagr1y	106.72%
Cagr3y	17.78%
Cagr5y	-53.49%
EPS Growth Years	3
FCF Growth Q	26.18%
OCF Growth Q	26.51%
Revenue Growth	2x
Revenue Growth Q	-6.51x
Revenue Growth Years	1x
Revenue Growth3 Y	-15.97x
Revenue Growth5 Y	3.92x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.53
Assets	$122M
Cash	$30M
Current Assets	$76.2M
Current Liabilities	$65.6M
Debt	$22.1M
Debt EBITDA	$5.01
Debt Equity	$1.56
Equity	$14.2M
Interest Coverage	-0.15
Liabilities	$107.8M
Long Term Assets	$45.8M
Long Term Liabilities	$42.2M
Net Cash	$7.9M
Net Cash By Market Cap	$29.53
Net Cash Growth	143.22%
Net Debt EBITDA	$-1.97
Net Debt Equity	$-0.56
Tangible Book Value	$-29.4M
Tangible Book Value Per Share	$-2.74
WACC	7.55

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.16
Inventory Turnover	2.1
Net Working Capital	$-8.2M
Quick ratio	0.93
Working Capital	$10.7M
Working Capital Turnover	$12.94

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-38.73%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-100%
1Y total return	106.61%
200-day SMA	2.4
3Y total return	63.4%
50-day SMA	2.59
50-day SMA vs 200-day SMA	50over200
5Y total return	-97.82%
All Time High	11,331,775.7
All Time High Change	-100%
All Time High Date	2015-04-24
All Time Low	0.95
All Time Low Change	163.16%
All Time Low Date	2025-04-07
ATR	0.1
Beta	0.28
Beta1y	2.59
Beta2y	1.66
Ch YTD	-3.85
High	2.54
High52	3.07
High52 Date	2026-01-05
High52ch	-18.43%
Low	2.49
Low52	1.2
Low52 Date	2025-05-08
Low52ch	108.33%
Ma50ch	-3.59%
Price vs 200-day SMA	4.3%
RSI	44.56
RSI Monthly	11.29
RSI Weekly	51.96
Sharpe ratio	1.03x
Sortino ratio	2.76
Total Return	-38.73%
Tr YTD	-3.85
Tr1m	-2.72%
Tr1w	-4.21%
Tr3m	4.6%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	3
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$-0.4
Earnings Revenue Estimate	12,042,136x
Earnings Revenue Estimate Growth	-34.74x
Operating Income	$-413,000
Operating margin	-0.66
Price target	$9.33
Price Target Change	$273

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	7,608,440%
Float Percent	70.89%
Net Borrowing	5,063,000
Shares Insiders	5.63%
Shares Institutions	17.35%
Shares Out	10,733,208
Shares Qo Q	-48.47%
Shares Yo Y	38.73%
Short Float	6.6%
Short Ratio	11.17
Short Shares	4.68

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-1.3M
Average Volume	31,066.15x
Bv Per Share	1.32
CAPEX	$-103,000
Ch10y	-100
Ch1m	-2.72
Ch1w	-4.21
Ch1y	106.6
Ch3m	4.6
Ch3y	63.4
Ch5y	-97.82
Ch6m	23.15
Change	1.21%
Change From Open	0.44
Close	2.47
Days Gap	0.77
Depreciation Amortization	4,439,000
Dollar Volume	19,315
Earnings Date	2026-05-13
Earnings Time	amc
EBIT	$-413,000
EBITDA	$4M
EPS	$-3.02
F Score	3
FCF	$-698,000
FCF EV Yield	-3.69x
FCF Per Share	$-0.07
Financing CF	13,325,000
Fiscal Year End	June
Income Tax	$315,000
Investing CF	-3,103,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-02-03
Last Report Date	2025-12-31
Last Split Date	2023-01-06
Last Split Type	Reverse
Last10k Filing Date	2025-09-23
Ma150	2.43
Ma150ch	2.71%
Ma20	2.56
Ma20ch	-2.23%
Net CF	9,627,000
Next Earnings Date	2026-05-13
Open	2.49
Optionable	No
Position In Range	22
Post Close	2.5
Postmarket Change Percent	-0.4
Postmarket Price	$2.49
Ppne	1,443,000
Price Date	2026-05-08
Price EBITDA	$6.66
Relative Volume	0.25x
Revenue	62,640,000x
SBC By Revenue	1.04x
Share Based Comp	649,000
Tax By Revenue	0.5x
Tr6m	23.15%
Us State	Colorado
Volume	7,726
Z Score	-3.23

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does AYTU pay a dividend?

Capital-return profile for this ticker.

Performance

AYTU stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns AYTU?

Insider, institutional, and short-interest positioning.

Institutional ownership

+17.4%

Float: +70.9% of shares outstanding

Insider ownership

+5.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

AYTU momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

44.6

Neutral momentum band

Price vs 200-day MA

+4.3%

50/200-day relationship not available

Beta (5Y)

0.28

Less volatile than the market

Sharpe ratio

1.03

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About AYTU

Hub-level FAQ points readers to the deeper analysis pages.

What is the current AYTU stock rating?

Aytu BioPharma, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full AYTU analysis?

The full report lives at /stocks/AYTU/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for AYTU?

The latest report frames AYTU around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the AYTU page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.